Complications of Immunoglobulin Therapy and Implications for Treatment of Inflammatory Neuropathy : A Review
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: Intravenous Immunoglobulin (IVIg) forms a cornerstone of effective treatment for acute and chronic inflammatory neuropathies, with a class I evidence base in Guillain-Barré Syndrome (GBS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and multifocal motor neuropathy (MMN). It is generally considered to be a safe therapy however there are several recognised complications which are reviewed in this article.
DISCUSSION AND CONCLUSION: Most adverse events are immediate and mild such as headache, fever and nausea although more serious immediate reactions such as anaphylaxis may rarely occur. Delayed complications are rare but may be serious, including thromboembolic events and acute kidney injury, and these and associated risk factors are also discussed. We emphasise the importance of safe IVIg administration and highlight practical measures to minimise complications of this therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Current drug safety - 14(2019), 1 vom: 19., Seite 3-13 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abbas, Ahmed [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adverse event |
|---|
| Anmerkungen: |
Date Completed 10.05.2019 Date Revised 10.05.2019 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1574886313666181017121139 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM289676231 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM289676231 | ||
| 003 | DE-627 | ||
| 005 | 20231225063054.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1574886313666181017121139 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0965.xml |
| 035 | |a (DE-627)NLM289676231 | ||
| 035 | |a (NLM)30332974 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Abbas, Ahmed |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Complications of Immunoglobulin Therapy and Implications for Treatment of Inflammatory Neuropathy |b A Review |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.05.2019 | ||
| 500 | |a Date Revised 10.05.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: Intravenous Immunoglobulin (IVIg) forms a cornerstone of effective treatment for acute and chronic inflammatory neuropathies, with a class I evidence base in Guillain-Barré Syndrome (GBS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and multifocal motor neuropathy (MMN). It is generally considered to be a safe therapy however there are several recognised complications which are reviewed in this article | ||
| 520 | |a DISCUSSION AND CONCLUSION: Most adverse events are immediate and mild such as headache, fever and nausea although more serious immediate reactions such as anaphylaxis may rarely occur. Delayed complications are rare but may be serious, including thromboembolic events and acute kidney injury, and these and associated risk factors are also discussed. We emphasise the importance of safe IVIg administration and highlight practical measures to minimise complications of this therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Adverse event | |
| 650 | 4 | |a CIDP | |
| 650 | 4 | |a GBS | |
| 650 | 4 | |a IVIg | |
| 650 | 4 | |a MMN | |
| 650 | 4 | |a immunoglobulin | |
| 650 | 4 | |a inflammatory neuropathy | |
| 650 | 4 | |a safety. | |
| 650 | 7 | |a Immunoglobulins, Intravenous |2 NLM | |
| 700 | 1 | |a Rajabally, Yusuf A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current drug safety |d 2006 |g 14(2019), 1 vom: 19., Seite 3-13 |w (DE-627)NLM181475790 |x 2212-3911 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2019 |g number:1 |g day:19 |g pages:3-13 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1574886313666181017121139 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2019 |e 1 |b 19 |h 3-13 | ||